Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Articles by Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Latest Updated Articles
Asciminib May Be an “Attractive” Option in Newly Diagnosed CML PopulationsPublished: June 1st 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
2
Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC
3
Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma
4
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
5
